The "Sweat Soaking Method"-processed Radix Wikstroemia indica Extracts Attenuate Liver Toxicity and its Effect on Cytochrome P450 Protein

Background: Radix Wikstroemia indica (RWI) is one of the most commonly used drugs in Miao medicine. However, RWI is characterized by high toxicity. Objectives: In this study, we aimed to observe the effect of the "sweat soaking method" processed on reducing the hepatotoxicity of RWI and on cytochrome P450 (CYP) protein expression. Materials and Methods: The study focused on investigating the impact of both RWI raw products and RWI processed products on the proliferation of L-02 cells. To assess this, a cell counting kit-8 was employed. After the administration of RWI through oral gavage for a duration of 15 days in rats, the corresponding kits were utilized to determine the serum levels of the liver index factor. Furthermore, both hematoxylin and eosin (H&E) staining and western blot analysis were conducted to analyze the liver tissues. Results: Both the raw RWI and the processed RWI at high doses inhibited the proliferation of L-02 cells, but the cell viability of the concoction group was higher than that of the raw group. The liver tissues of rats in the control and processed product groups were normal, while those in the raw product groups showed different degrees of liver damage. Additionally, compared with the control group, the activity of alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine transaminase (ALT) in the raw product groups was notably increased in a dose-dependent manner; the three enzyme activities of the processed group were lower than those of the raw product group. In addition, the expression levels of CYP3A4, 2C19, 2C9, 1A2, and 2E1 in the liver tissue of rats in the processed group were lower than those in the raw group, while the protein expression trend of CYP2D6 was irregular. Conclusion: The detoxication mechanism of RWI, after undergoing processing, appears to be associated with reduced protein expression of CYP1A2, CYP2E1, CYP2C9, CYP2C19, and CYP3A4, ultimately leading to decreased liver injury.